Skip to content

UNICLE BIOMEDICAL DATA SCIENCE

Active
Private limited companyfounded 20215 yrs activeKapeldreef 60, 3001 Leuven, BelgiumKBO/BCE: BE 0770.950.357

UNICLE BIOMEDICAL DATA SCIENCE has been active since 2021 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €173k and a net result of €-67k. Equity is growing by ~21% per year across the filed fiscal years. Its solvency ranks better than 90% of 16989 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is 0.5% (very low).

Checked score

Score 2025
72 / 100
Healthy
The score weighs solvency, liquidity and profitability. Bankruptcy probability contributes 35%. Every signal that weighs is under Signals.
Axes · tick = 2024
Profitability0▼-100
Solvency100=
Growth52▼-26
Track record94
Bankruptcy probability, 12 months
0.5% Very low
0%0.5%1.5%4%10%≥ 25%
Credit up to €12k at 30 days acceptable
Liquidity ample (current ratio 20.47 against 6.98 in 2024; short-term debt: 4.7% and cash: 62.3% of total assets), and 8.3% of the assets are financed with debt.
Credit advice for your own amount and term

Signals

Five signals. The signal on the left, the evidence on the right.
lowers risk+raises riskneutral
lowers risk · Lower-failure-rate sector
In this sector companies fail less often than the Belgian average.
Gazette · bankruptcies per sector, NACE 62
Relative position
BE, all sectors
reference
Sector 62
lower
← fewer bankruptcies more bankruptcies →
raises risk · Limited track record
This company has not been active as long as an established one and statistically fails somewhat more often.
KBO · incorporation date
Age against the risk zone
elevated failure risk from 2 to 8 years 5 years 0 10 y
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 02-07-2026, 29 days ahead of the deadline.
NBB · 4 filings
Deviation from the deadline
2025
29 d early
2024
57 d late
2023
16 d early
2022
14 d early
← before the deadline after the deadline →
neutral · The next deadline is still running
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today.
Companies Code · seven months
Position in the running window
19-09-2026 today31-12-2026 close31-07-2027 deadline
neutral · No strike-offs in the KBO publications
We found no ex-officio strike-off or cessation. Our series starts in 2021 and has gaps, so this is not a confirmation that there is nothing.
KBO publications · our coverage

Financials · fiscal year 2025, micro schema

Equity
€173k▼ 27.9%
2024 · €240k
2022: €83k 2023: €113k 2024: €240k
2022 → 2025
Total assets
€188k▼ 34.6%
2024 · €288k
2022: €257k 2023: €382k 2024: €288k
2022 → 2025
Net result
€-67k
2024 · €127k
2022: €108k 2023: €30k 2024: €127k
2022 → 2025
Working capital
€174k▼ 27.2%
2024 · €239k
2022: €71k 2023: €182k 2024: €239k
2022 → 2025
Multi-year overview
Every figure with its change against the year before
▲ rise ▼ fall
Line2022202320242025Trend
Equity€83k-€113k▲ 35.7%€240k▲ 113%€173k▼ 27.9%
Operating result€132k-€39k▼ 70.6%€126k▲ 226%€-67k
Net result€108k-€30k▼ 72.5%€127k▲ 328%€-67k
Turnover and EBIT margin not published: the micro schema does not require them.
Result per fiscal year
Operating resultNet result
€-100k€-50k€0€50k€100k€150kOperating result 2022: €132k€132kNet result 2022: €108k€108kOperating result 2023: €39k€39kNet result 2023: €30k€30kOperating result 2024: €126k€126kNet result 2024: €127k€127kOperating result 2025: €-67k€-67kNet result 2025: €-67k€-67k2022202320242025
The operating result turns negative in 2025: a loss of €67k after €126k in 2024, the lowest result in the available series.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Assets €188k
Fixed assets €6k▼ 38.0%
Current assets €183k▼ 34.4%
Equity and liabilities €188k
Equity €173k▼ 27.9%
Debt €16k▼ 67.5%
The debt ratio falls from 16.8% to 8.3%. Equity and debt are lower.
Key figures and ratios
2025 value · change against 2024
EBITDA
€-64k
2024 · €130k
Cash flow
€-63k
2024 · €131k
Solvency
91.7%
2024 · 83.2%
Current ratio
20.47
2024 · 6.98
Quick ratio
20.47
2024 · 6.98
Debt / equity
0.09
2024 · 0.20
ROE
-38.7%
2024 · 53.0%
ROA
-35.5%
2024 · 44.1%
Interest coverage
-198.41
2024 · 364.04
Debt
€16k
2024 · €48k
Debt ≤ 1 year
€9k
2024 · €40k
Staff costs
€4k
2024 · €53k
Green means a favourable move, even when the figure itself falls: as with debt or debt / equity.
Filed annual accounts
As filed with the NBB · 2025 against 2024
Balance sheet Code20242025
Assets
Total assets20/58€288k€188k
Fixed assets21/28€9k€6k
Intangible fixed assets21€3k€3k
Tangible fixed assets22/27€5k€2k
Plant, machinery and equipment23€104-
Furniture and vehicles24€5k€2k
Financial fixed assets28€1k€1k=
Current assets29/58€279k€183k
Amounts receivable within one year40/41€35k€60k
Trade receivables40€27k€55k
Other amounts receivable41€8k€5k
Cash at bank and in hand54/58€243k€117k
Deferred charges and accrued income490/1-€5k
Equity and liabilities
Total equity and liabilities10/49€288k€188k
Equity10/15€240k€173k
Contributions10/11€5k€5k=
Profit (loss) carried forward14€235k€168k
Amounts payable17/49€48k€16k
Amounts payable within one year42/48€40k€9k
Trade debts44€34k€9k
Suppliers440/4€34k€9k
Taxes, remuneration and social security45€6k-
Remuneration and social security454/9€6k-
Other amounts payable47/48-€295
Accrued charges and deferred income492/3€8k€7k
Income statement Code20242025
Remuneration, social security and pensions62€53k€4k
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€4k€3k
Write-downs on stocks, contracts in progress and trade receivables: additions (reversals)631/4-€-21k
Other operating charges640/8€387€22k
Gross operating margin9900€184k€-59k
Operating profit (loss)9901€126k€-67k
Financial income75/76B€1k€894
Recurring financial income75€1k€894
Financial charges65/66B€357€322
Recurring financial charges65€357€322
Profit (loss) for the period before taxes9903€127k€-67k
Profit (loss) for the period9904€127k€-67k
Profit (loss) for the period to be appropriated9905€127k€-67k
Appropriation of the result
Profit (loss) to be appropriated9906€235k€168k
Profit (loss) brought forward from the previous period14P€108k€235k

The notes to these accounts (8 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.

Download as CSV

Timeline · acts, filings and financial milestones

Next filing, fiscal year 2026, expected by 31-07-2027
2026
07-08
State Gazette act Resignations & appointments
General meeting · Director resignation · Director discharge8 facts ▸
  • General meeting, 29/06/2026
  • Director resignation, JSVC Advies BV (bestuurder)
  • Director resignation, Horizons.Bio BV (bestuurder)
  • Director resignation, Jermaine Goveia (gedelegeerd bestuurder)
  • Director discharge, JSVC Advies BV
  • Director discharge, Horizons.Bio BV
  • Permanent representative, Jasper Smink
  • Permanent representative, Jermaine Goveia
02-07
NBB filing Annual accounts filed
fiscal year 2025 · micro schema
2025
31-12
Financial Weakest financial yearnet €-67k ▼153%
Net result drops to €-67k, the lowest in the series.
31-12
Financial Liquidity triplescurrent ratio 20.47
Current ratio from 6.98 to 20.47; short-term debt falls from €40k to €9k.
26-09
NBB filing Annual accounts filed
fiscal year 2024 · micro schema · 57 days late
2024
31-12
Financial Highest result since 2022net €127k ▲328%
Net result €127k, the highest in the series.
31-12
Financial Liquidity quadruplescurrent ratio 6.98
Current ratio from 1.97 to 6.98; short-term debt falls from €188k to €40k.
31-12
Financial Equity above €200kEq €240k ▲113%
3 profitable years in a row build equity to €240k.
15-07
NBB filing Annual accounts filed
fiscal year 2023 · micro schema
2023
31-12
Financial Equity above €100kEq €113k ▲35.7%
2 profitable years in a row build equity to €113k.
17-07
NBB filing Annual accounts filed
fiscal year 2022 · micro schema
Financial milestoneState Gazette actNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.

Directors · office · real estate

Directors
no sitting director, no change since 2026
We have established no sitting directors for this company. We derive directors from published Gazette acts; while there are none, or none read, nothing appears here. That does not mean the company has none: the CBE keeps its own list of function holders, which we do not read.
29-06-2026 Horizons.bio: Resigned as Director
29-06-2026 Jermaine Goveia: Resigned as Managing director
Location & real-estate footprint
Registered office, Leuven · 1 establishment unit since 2021
establishment The establishment unit on the map
Cannot be placed on the map

This address could not be matched to a point in the Belgian address register (BOSA BEST). The address below comes straight from the Crossroads Bank.

Kapeldreef 603001 Leuven
Ground area
8,837 m²
Building footprint
2,096 m²
Volume, LiDAR
12,516 m³
Parcel 24040C0005/00F000, Flanders · tallest building 8.1 m, ±2 floors. Linked by address, not a title deed.
1 establishment unit
UNICLE BIOMEDICAL DATA SCIENCE
Kapeldreef 60, 3001 LeuvenIT consultancy
since 20212.319.674.331
1 parcel
Flanders 1 (100%)
Parcel (capakey) Region Area Buildings Height / fl.
24040C0005/00F000 Flanders 8,837 m² 1 · 2,096 m² 8.1 m · 2 fl.
Linked by address, not proof of ownership
Methodology
via registered seat: 1
1 of 1 parcel with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.

Public money · subsidies and aid

Flemish government

2024 to 2025 · 3 entries · 282,068 EUR awarded · 224,000 EUR paid
Year Entries awardedpaid
2025 2 0 EUR0 EUR
2024 1 282,068 EUR224,000 EUR
Schemes
Ontwikkelingsproject
3 entries · 282,068 EUR · 224,000 EUR paid · Fonds voor Innoveren en Ondernemen

Similar companies · same sector, comparable size

Of 29,995 companies in sector 62200 we hold annual accounts for 18,391. 15,183 are within a factor 10 of this equity.See the whole sector

Company data · Crossroads Bank

Identification
Legal formPrivate limited company
Founded09-07-2021
Fiscal year end31-12
Abbreviation NL UNICLE BDS
Activities, NACEBEL
62020IT consultancy
62200Computer consultancy and computer facilities management
72101Research and development on biotechnology
62900Other information technology and computer services
63100Computing infrastructure, data processing, hosting and related activities
63110Computing infrastructure, data processing, hosting and other information service activities
63920Other information service activities
63990Computing infrastructure, data processing, hosting and other information service activities
70200Business and other management consultancy
70220Business consulting
Sources
Crossroads Bank for EnterprisesNational Bank · 4 filingsAddress and cadastre registers

Data from official sources, last processed on 19-09-2026. Scores and ratios are computed by Checked and are not a credit decision.